Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL308634 | 0.89 | TSHR (0.41) | ALDH1A1POLBGAALMNAMEN1 | |
| SCHEMBL26972806 | 0.85 | ALDH1A1 (0.45) | ALDH1A1POLBGAASOAT1LMNA | |
| SCHEMBL2299704 | 0.85 | ALDH1A1 (0.48) | ALDH1A1POLBGAASOAT1LMNA | |
| SCHEMBL3399500 | 0.85 | ALDH1A1 (0.48) | ALDH1A1POLBGAASOAT1LMNA | |
| SCHEMBL28384378 | 0.85 | POLB (0.38) | ALDH1A1POLBGAALMNAMEN1 | |
| SCHEMBL20019668 | 0.83 | HTT (0.50) | ALDH1A1POLBGAALMNAMEN1 | |
| SCHEMBL308783 | 0.83 | POLB (0.45) | ALDH1A1POLBGAALMNAMEN1 | |
| SCHEMBL17923615 | 0.80 | TSHR (0.37) | ALDH1A1POLBGAALMNAMEN1 | |
| SCHEMBL22735055 | 0.80 | ALDH1A1 (0.38) | ALDH1A1POLBGAALMNAMEN1 | |
| SCHEMBL20019752 | 0.80 | TSHR (0.37) | ALDH1A1POLBGAALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106716691-A | Lithium battery electrolyte solution containing ethyl (2,2,3, 3-tetrafluoropropyl) carbonate | 陶氏环球技术有限责任公司 | 2017-05-24 | — | — | CN | claimed |
| EP-4736255-A2 | SPIROBISINDANE COPOLYMERS AND METHODS OF MAKING | Sepion Technologies, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260094872-A1 | TERNARY SOLVENT ELECTROLYTES FOR HIGH VOLTAGE AND HIGH RATE LITHIUM BATTERIES | SEPION TECH INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4637732-A1 | SPIROBISINDANE POLYMERS OF INTRINSIC MICROPOROSITY AND METHODS OF MAKING | Sepion Technologies, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4595143-A1 | TERNARY SOLVENT ELECTROLYTES FOR HIGH VOLTAGE AND HIGH RATE LITHIUM BATTERIES | Sepion Technologies, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| CN-120202571-A | Ternary solvent electrolyte for high voltage and high rate lithium battery | 赛鹏科技有限公司 | 2025-06-24 | — | — | CN | disclosed |
| WO-2025006736-A9 | SPIROBISINDANE COPOLYMERS AND METHODS OF MAKING | SEPION TECHNOLOGIES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025006736-A2 | SPIROBISINDANE COPOLYMERS AND METHODS OF MAKING | SEPION TECHNOLOGIES, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20240262960-A1 | SPIROBISINDANE POLYMERS OF INTRINSIC MICROPOROSITY AND METHODS OF MAKING | SEPION TECHNOLOGIES, INC. | 2024-08-08 | — | — | US | disclosed |
| WO-2024137989-A1 | SPIROBISINDANE POLYMERS OF INTRINSIC MICROPOROSITY AND METHODS OF MAKING | SEPION TECHNOLOGIES, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-106663800-A | Lithium battery electrolyte solution containing methyl (2,2,3, 3-tetrafluoropropyl) carbonate | 陶氏环球技术有限责任公司 | 2017-05-10 | — | — | CN | disclosed |
| EP-3151326-A1 | NONAQUEOUS ELECTROLYTE AND ELECTRICITY-STORING DEVICE IN WHICH SAME IS USED | Ube Industries, Ltd. (JP) | 2017-04-05 | — | — | EP | disclosed |
| US-20150118577-A1 | LITHIUM SECONDARY BATTERY | NEC CORPORATION (JP) | 2015-04-30 | — | — | US | disclosed |
| EP-2247686-B1 | HEAT TRANSFER APPARATUS AND METHODS INCLUDING HYDROFLUOROCARBONATES | 3M INNOVATIVE PROPERTIES CO (US) | 2014-12-24 | — | — | EP | disclosed |
| CN-104247139-A | Lithium secondary battery | NEC CORP | 2014-12-24 | — | — | CN | disclosed |
| US-8003004-B2 | Heat transfer apparatus and methods including hydrofluorocarbonates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2247686-A1 | HEAT TRANSFER APPARATUS AND METHODS INCLUDING HYDROFLUOROCARBONATES | 3M Innovative Properties Company (US) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009094278-A1 | HEAT TRANSFER APPARATUS AND METHODS INCLUDING HYDROFLUOROCARBONATES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-07-30 | — | — | WO | disclosed |
| US-20090183856-A1 | HEAT TRANSFER APPARATUS AND METHODS INCLUDING HYDROFLUOROCARBONATES | 3M INNOVATIVE PROPERTIES COMPANY | 2009-07-23 | — | — | US | disclosed |
| CN-101218706-A | Nonaqueous electrolyte solution, nonaqueous electrolyte secondary battery, and carbonate compound | MITSUBISHI CHEM CORP (JP) | 2008-07-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260094872-A1 | TERNARY SOLVENT ELECTROLYTES FOR HIGH VOLTAGE AND HIGH RATE LITHIUM BATTERIES | CACNA1C, TIMCC, SLC8A1 | ALDH1A1 4363/4885POLB 3606/4885GAA 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.